NOT FOR DISTRIBUTION
Header cover image

Market Cap

CN¥5.6b

Last Updated

2021/04/11 09:14 UTC

Data Sources

Company Financials

Executive Summary

Chimin Health Management Co., Ltd. develops, produces, and sells human drugs and medical devices in China. More Details


Snowflake Analysis

Solid track record with imperfect balance sheet.

Share Price & News

How has Chimin Health Management's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 603222 is more volatile than 90% of CN stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: 603222's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of CN stocks.


Market Performance


7 Day Return

4.3%

603222

-0.1%

CN Pharmaceuticals

-1.1%

CN Market


1 Year Return

-62.9%

603222

15.8%

CN Pharmaceuticals

28.4%

CN Market

Return vs Industry: 603222 underperformed the CN Pharmaceuticals industry which returned 14.4% over the past year.

Return vs Market: 603222 underperformed the CN Market which returned 27.4% over the past year.


Shareholder returns

603222IndustryMarket
7 Day4.3%-0.1%-1.1%
30 Day4.8%3.9%1.0%
90 Day55.5%-5.4%-5.8%
1 Year-62.8%-62.9%16.9%15.8%30.4%28.4%
3 Yearn/a25.2%20.7%25.9%19.9%
5 Year17.7%16.3%41.6%34.1%23.6%15.5%

Long-Term Price Volatility Vs. Market

How volatile is Chimin Health Management's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Chimin Health Management undervalued compared to its fair value and its price relative to the market?

86.89x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 603222 (CN¥17.37) is trading above our estimate of fair value (CN¥0.55)

Significantly Below Fair Value: 603222 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 603222 is poor value based on its PE Ratio (86.9x) compared to the CN Pharmaceuticals industry average (30.9x).

PE vs Market: 603222 is poor value based on its PE Ratio (86.9x) compared to the CN market (34.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 603222's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 603222 is overvalued based on its PB Ratio (6.4x) compared to the CN Pharmaceuticals industry average (2.8x).


Future Growth

How is Chimin Health Management forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chimin Health Management has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Chimin Health Management performed over the past 5 years?

1.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 603222 has high quality earnings.

Growing Profit Margin: 603222's current net profit margins (7.9%) are higher than last year (5%).


Past Earnings Growth Analysis

Earnings Trend: 603222's earnings have grown by 1.2% per year over the past 5 years.

Accelerating Growth: 603222's earnings growth over the past year (70.6%) exceeds its 5-year average (1.2% per year).

Earnings vs Industry: 603222 earnings growth over the past year (70.6%) exceeded the Pharmaceuticals industry 10.9%.


Return on Equity

High ROE: 603222's Return on Equity (5.1%) is considered low.


Financial Health

How is Chimin Health Management's financial position?


Financial Position Analysis

Short Term Liabilities: 603222's short term assets (CN¥694.9M) do not cover its short term liabilities (CN¥863.5M).

Long Term Liabilities: 603222's short term assets (CN¥694.9M) exceed its long term liabilities (CN¥234.4M).


Debt to Equity History and Analysis

Debt Level: 603222's debt to equity ratio (79.4%) is considered high.

Reducing Debt: Insufficient data to determine if 603222's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 603222's debt is not well covered by operating cash flow (14.9%).

Interest Coverage: 603222's interest payments on its debt are well covered by EBIT (3.2x coverage).


Balance Sheet


Dividend

What is Chimin Health Management current dividend yield, its reliability and sustainability?

0.28%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 603222's dividend (0.28%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.42%).

High Dividend: 603222's dividend (0.28%) is low compared to the top 25% of dividend payers in the CN market (1.79%).


Stability and Growth of Payments

Stable Dividend: 603222 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 603222 has only been paying a dividend for 6 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (24%), 603222's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

CN¥414k

CEO Compensation


CEO

Yunfei Tian (38 yo)

no data

Tenure

CN¥414,000

Compensation

Mr. Yunfei Tian serves as General Manager and Director of Chimin Health Management Co., Ltd. (formerly known as Zhejiang Chimin Pharmaceutical CO.,Ltd). Mr. Tian served as Manager of the Production Departm...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Chimin Health Management Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chimin Health Management Co., Ltd.
  • Ticker: 603222
  • Exchange: SHSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥5.558b
  • Shares outstanding: 320.00m
  • Website: https://www.chimin.cn

Number of Employees


Location

  • Chimin Health Management Co., Ltd.
  • 888 North Road
  • Huangyan
  • Zhejiang Province
  • 318020
  • China

Listings


Biography

Chimin Health Management Co., Ltd. develops, produces, and sells human drugs and medical devices in China. The company offers non-PVC soft bag double tube double valves, single valves, and single-tube doub...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 09:14
End of Day Share Price2021/04/09 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.